A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

Item
http://www.wikidata.org/entity/Q34238046
Kinesin-5: cross-bridging mechanism to targeted clinical therapyTargeting the Mitotic Catastrophe Signaling Pathway in CancerThe mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma.KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTLOncogenic role of kinesin proteins and targeting kinesin therapy.Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present).Interphase microtubules: chief casualties in the war on cancer?Use of Three-Dimensional Arterial Models To Predict the In Vivo Behavior of Nanoparticles for Drug Delivery.Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells.A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells.Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation.Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cellsStructure-Guided Design of Novel l-Cysteine Derivatives as Potent KSP Inhibitors.A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?: Brain tumors and microcephaly arise from opposing derangements regulating progenitor growth. Drivers of microcephaly could be attractive brain tumor targets.
P2860

A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias

Item
http://www.wikidata.org/entity/Q34238046
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@ast
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@en
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@nl
type
label
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@ast
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@en
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@nl
prefLabel
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@ast
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@en
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
A phase 1 dose-escalation stud ...... ith advanced myeloid leukemias
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932